This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results- 2Warnakula, Samantha
- 1Borthwick, Faye
- 1Cheeseman, Christopher I.
- 1Hassanali, Zahra
- 1Mangat, Rabban
- 1Proctor, Spencer D.
- 1Agricultural, Food and Nutritional Science, Department of
- 1Agricultural, Food and Nutritional Science, Department of/Journal Articles (Agricultural, Food and Nutritional Science)
- 1Graduate and Postdoctoral Studies (GPS), Faculty of
- 1Graduate and Postdoctoral Studies (GPS), Faculty of/Theses and Dissertations
-
Arterial retention of remnant lipoproteins ex-vivo is increased during insulin resistance due to increased arterial biglycan and production of cholesterol-rich atherogenic particles, that can be improved by ezetimibe in the JCR:LA-cp rat
Download2012
Russell, James C., Proctor, Spencer D., Uwiera, Richard R. E., Vine, Donna F., Mangat, Rabban, Hassanali, Zahra, Cheeseman, Christopher I., Borthwick, Faye, Warnakula, Samantha
Background Literature supports the “response-to-retention” hypothesis—that during insulin resistance, impaired metabolism of remnant lipoproteins can contribute to accelerated cardiovascular disease progression. We used the JCR:LA-cp rat model of metabolic syndrome (MetS) to determine the extent...
-
The role of ezetimibe and simvastatin in modulating intestinal cholesterol transport, chylomicron profile and chylomicron-remnant uptake by the arterial wall in a rodent model of the metabolic syndrome
DownloadFall 2010
Intestinally derived chylomicron remnants (CM-r) may contribute to atherogenic dyslipidemia during the Metabolic Syndrome (Mets). However, the combined effects of ezetimibe (EZ) and simvastatin (SV) on post-prandial (PP) dyslipidemia during MetS remains unclear, nor is it known whether the...